BPMC - Blueprint Medicines: Overdue For A Breather

2024-07-16 10:20:24 ET

Summary

• Today, we take a look at Blueprint Medicines Corporation, a company focused on developing precision therapies for cancers and blood disorders.
• Blueprint's Q1 results were spectacular, and the company has a solid balance sheet, but the stock is up more than 150% from its lows in late October.
• Can the shares rally further, or are they overdue for a breather?  An analysis follows in the paragraphs below.

Today, we put Blueprint Medicines Corporation ( BPMC ) in the spotlight for the first time in a while . The stock of this commercial stage biopharma has more than doubled since the overall market swoon ended late last October. Can the good times continue in the months ahead? An analysis follows below....

For further details see: